Mark P Rogan

Mark P Rogan

Auto-generated profile, based on publicly available information

Mark P Rogan

Department of Respiratory Medicine, Mater Misercordiae University Hospital, Eccles Street, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2006 in Respiratory Research
Verified
Journal Article
Open access
PDF file
MRMark P Rogan
Mark P Rogan
Patrick GeraghtyPatrick Geraghty
Patrick Geraghty
Catherine GreeneCatherine Greene
Catherine Greene
SOShane J O'Neill
Shane J O'Neill
Clifford C. TaggartClifford C. Taggart
Clifford C. Taggart
NMNoel G McElvaney
Noel G McElvaney
Inspired air contains a myriad of potential pathogens, pollutants and inflammatory stimuli. In the normal lung, these pathogens are rarely problematic. This is because the epithelial lining fluid in the lung is rich in many innate immunity proteins and peptides that provide a powerful anti-microbial screen. These defensive proteins have anti-bacterial, anti- viral and in some cases, even anti-fungal properties. Their antimicrobial effects are as diverse as inhibition of biofilm formation and prevention of viral replication. The innate immunity proteins and peptides also play key immunomodulatory roles. They are involved in many key processes such as opsonisation facilitating phagocytosis of bacteria and viruses by macrophages and monocytes. They act as important mediators in inflammatory pathways and are capable of binding bacterial endotoxins and CPG motifs. They can also influence expression of adhesion molecules as well as acting as powerful anti-oxidants and anti-proteases. Exciting new antimicrobial and immunomodulatory functions are being elucidated for existing proteins that were previously thought to be of lesser importance. The potential therapeutic applications of these proteins and peptides in combating infection and preventing inflammation are the subject of ongoing research that holds much promise for the future.

5 September 2007 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
MRMark P Rogan
Mark P Rogan
KTKarl Thomas
Karl Thomas
A 78-year-old white male from Iowa in the United States of America receiving the anti- tumor necrois factor (TNF) agent infliximab therapy for rheumatoid arthritis developed a cheek ulcer which failed to respond to empiric antibiotic therapy. He subsequently presented with progressive respiratory failure from miliary coccidioidomycosis which proved fatal. The patient vacationed in Arizona 6 months previously and likely contracted the organism there as Iowa is not an endemic area for coccidioidomycosis. Respiratory failure from miliary infiltration is an uncommon presentation of coccidioidomycosis. Physicians should be aware of the importance of travel history and potential for life-threatening coccidioidomycosis in patients receiving tumor necrosis factor inhibitors.

24 September 2008 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
MRM. P. Rogan
M. P. Rogan
BMB. Marsh
B. Marsh